Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Dec;63(12):1564–1570. doi: 10.1136/ard.2003.017269

Divergent roles of nitrergic and prostanoid pathways in chronic joint inflammation

S Day 1, J Lockhart 1, W Ferrell 1, J McLean 1
PMCID: PMC1754842  PMID: 15547079

Abstract

Background: Nitrergic and prostanoid pathways have both been implicated in inflammatory processes.

Objective: To investigate their respective contributions in a rat model of chronic arthritis.

Methods: Male Wistar rats (n = 4–6/group) received either an intra-articular injection of 2% carrageenan/4% kaolin (C/K) or intra- and periarticular injections of Freund's complete adjuvant (FCA; 10 mg/ml M tuberculosis). Joint diameter, urinary nitric oxide metabolites (NOx), and prostaglandin E2 (PGE2) levels were measured as indices of the inflammatory process. A prophylactic and therapeutic (day 5) dose ranging study of an inducible nitric oxide synthase inhibitor, L-N-(1-iminoethyl)-lysine (L-NIL), and a cyclo-oxygenase-2 (COX-2) inhibitor, SC-236, was performed with the drugs given subcutaneously. Submaximal doses were identified and used for combination studies. Appropriate vehicle controls were included.

Results: L-NIL and SC-236 dose dependently inhibited C/K induced acute joint swelling, the magnitude being greatest when they were given in combination. Both prophylactic and therapeutic administration of SC-236 in the FCA induced model of chronic arthritis produced a dose dependent reduction in all the measures assessed. However, although L-NIL demonstrated similar dose dependent inhibition of urinary NOx and PGE2 levels, joint swelling was significantly exacerbated in this model. Co-administration of the inhibitors nullified the benefits of SC-236.

Conclusion: Whereas COX-2 derived prostaglandins are proinflammatory in both acute and chronic joint inflammation, NO seems to have divergent roles, being anti-inflammatory in chronic and proinflammatory in acute joint inflammation.

Full Text

The Full Text of this article is available as a PDF (151.2 KB).

Figure 1.

Figure 1

Open in a new tab

 Acute inflammation: knee joint swelling (24 hours) induced by intra-articular injection of carrageenan and kaolin, expressed as a percentage change in knee joint diameter compared with preinjection values. L-NIL and SC-236 given in combination resulted in greater inhibition of knee joint swelling than either drug alone (p<0.01, two way ANOVA).

Figure 2.

Figure 2

Open in a new tab

 Chronic inflammation—prophylactic administration: (A) knee joint swelling; (B) urinary NOx; and (C) PGE2, expressed as a percentage change compared with preinjection values in response to intra-articular injection of FCA. There was significant joint swelling and increased NOx and PGE2 production in the vehicle, L-NIL (43 mg/kg), and SC-236 (5.6 mg/kg) prophylactically treated groups. A non-inflamed, untreated group is included for comparison. Values represent means (SEM).

Figure 3.

Figure 3

Open in a new tab

 Chronic inflammation—histology: (A) normal (untreated) knee joint; (B) 10 days after induction of FCA in SC-236 treated animals; (C) 10 days after induction of FCA in L-NIL treated animals. Sections stained with haematoxylin, safranin O, and fast green.

Figure 4.

Figure 4

Open in a new tab

 Chronic inflammation—therapeutic administration: (A) knee joint swelling; (B) urinary NOx; and (C) PGE2, expressed as a percentage change compared with pre-injection values in response to intra-articular injection of FCA. There was significant joint swelling and increased NOx and PGE2 production in vehicle, L-NIL (43 mg/kg), and SC-236 (5.6 mg/kg) therapeutically treated groups. A non-inflamed, untreated group is included for comparison. Values represent means (SEM).

Figure 5.

Figure 5

Open in a new tab

 Chronic inflammation—combined administration: Knee joint swelling, expressed as a percentage change compared with preinjection values in response to intra-articular injection of FCA. Combined administration of L-NIL (43 mg/kg) and SC-236 (5.6 mg/kg), (A) prophylactically or (B) therapeutically at days 9 and 14, respectively, as compared with untreated and vehicle treated controls. Data for independent administration of each of these drugs (from figs 2 and 3) are also included for comparison. Values represent means (SEM), n = 6/group. ***p<0.001 compared with untreated controls; ‡‡‡p<0.001 compared with vehicle treated inflamed animals; ††† p<0.001 compared with combination treatment inflamed animals (Bonferroni post hoc tests).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alderton W. K., Cooper C. E., Knowles R. G. Nitric oxide synthases: structure, function and inhibition. Biochem J. 2001 Aug 1;357(Pt 3):593–615. doi: 10.1042/0264-6021:3570593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bingham Clifton O., 3rd The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. J Rheumatol Suppl. 2002 Sep;65:3–9. [PubMed] [Google Scholar]
  3. Cepinskas G., Lush C. W., Kvietys P. R. Anoxia/reoxygenation-induced tolerance with respect to polymorphonuclear leukocyte adhesion to cultured endothelial cells. A nuclear factor-kappaB-mediated phenomenon. Circ Res. 1999 Jan 8;84(1):103–112. doi: 10.1161/01.res.84.1.103. [DOI] [PubMed] [Google Scholar]
  4. Cicala C., Ianaro A., Fiorucci S., Calignano A., Bucci M., Gerli R., Santucci L., Wallace J. L., Cirino G. NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis. Br J Pharmacol. 2000 Jul;130(6):1399–1405. doi: 10.1038/sj.bjp.0703449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Coleman J. W. Nitric oxide in immunity and inflammation. Int Immunopharmacol. 2001 Aug;1(8):1397–1406. doi: 10.1016/s1567-5769(01)00086-8. [DOI] [PubMed] [Google Scholar]
  6. Colville-Nash Paul R., Willoughby Derek A. COX-1, COX-2 and articular joint disease: a role for chondroprotective agents. Biorheology. 2002;39(1-2):171–179. [PubMed] [Google Scholar]
  7. Connor J. R., Manning P. T., Settle S. L., Moore W. M., Jerome G. M., Webber R. K., Tjoeng F. S., Currie M. G. Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur J Pharmacol. 1995 Jan 24;273(1-2):15–24. doi: 10.1016/0014-2999(94)00672-t. [DOI] [PubMed] [Google Scholar]
  8. Corbett J. A., Kwon G., Turk J., McDaniel M. L. IL-1 beta induces the coexpression of both nitric oxide synthase and cyclooxygenase by islets of Langerhans: activation of cyclooxygenase by nitric oxide. Biochemistry. 1993 Dec 21;32(50):13767–13770. doi: 10.1021/bi00213a002. [DOI] [PubMed] [Google Scholar]
  9. Crofford L. J., Wilder R. L., Ristimäki A. P., Sano H., Remmers E. F., Epps H. R., Hla T. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest. 1994 Mar;93(3):1095–1101. doi: 10.1172/JCI117060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Day S. M., McLean J. S., Lockhart J. C., Ferrell W. R. Combined inhibition of nitrergic and prostanoid pathways in J774 macrophages. Clin Exp Rheumatol. 2003 Sep-Oct;21(5):625–631. [PubMed] [Google Scholar]
  11. De Caterina R., Libby P., Peng H. B., Thannickal V. J., Rajavashisth T. B., Gimbrone M. A., Jr, Shin W. S., Liao J. K. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995 Jul;96(1):60–68. doi: 10.1172/JCI118074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Egan Colin G., Lockhart John C., Ferrell William R., Day Suzanne M., McLean John S. Pathophysiological basis of acute inflammatory hyperaemia in the rat knee: roles of cyclo-oxygenase-1 and -2. J Physiol. 2002 Mar 1;539(Pt 2):579–587. doi: 10.1113/jphysiol.2001.013473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Emery P. Clinical implications of selective cyclooxygenase-2 inhibition. Scand J Rheumatol Suppl. 1996;102:23–28. doi: 10.3109/03009749609097227. [DOI] [PubMed] [Google Scholar]
  14. Ferrell William R., Lockhart John C., Kelso Elizabeth B., Dunning Lynette, Plevin Robin, Meek Stephen E., Smith Andrew J. H., Hunter Gary D., McLean John S., McGarry Frances. Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest. 2003 Jan;111(1):35–41. doi: 10.1172/JCI16913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gierse J. K., McDonald J. J., Hauser S. D., Rangwala S. H., Koboldt C. M., Seibert K. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem. 1996 Jun 28;271(26):15810–15814. doi: 10.1074/jbc.271.26.15810. [DOI] [PubMed] [Google Scholar]
  16. Hood V. C., Cruwys S. C., Urban L., Kidd B. L. The neurogenic contribution to synovial leucocyte infiltration and other outcome measures in a guinea pig model of arthritis. Neurosci Lett. 2001 Feb 23;299(3):201–204. doi: 10.1016/s0304-3940(00)01790-0. [DOI] [PubMed] [Google Scholar]
  17. Khan B. V., Harrison D. G., Olbrych M. T., Alexander R. W., Medford R. M. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9114–9119. doi: 10.1073/pnas.93.17.9114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kinne R. W., Bräuer R., Stuhlmüller B., Palombo-Kinne E., Burmester G. R. Macrophages in rheumatoid arthritis. Arthritis Res. 2000 Apr 12;2(3):189–202. doi: 10.1186/ar86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. McCartney-Francis N. L., Song X., Mizel D. E., Wahl S. M. Selective inhibition of inducible nitric oxide synthase exacerbates erosive joint disease. J Immunol. 2001 Feb 15;166(4):2734–2740. doi: 10.4049/jimmunol.166.4.2734. [DOI] [PubMed] [Google Scholar]
  20. McCartney-Francis N., Allen J. B., Mizel D. E., Albina J. E., Xie Q. W., Nathan C. F., Wahl S. M. Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med. 1993 Aug 1;178(2):749–754. doi: 10.1084/jem.178.2.749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. McInnes I. B., Leung B. P., Field M., Wei X. Q., Huang F. P., Sturrock R. D., Kinninmonth A., Weidner J., Mumford R., Liew F. Y. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients. J Exp Med. 1996 Oct 1;184(4):1519–1524. doi: 10.1084/jem.184.4.1519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. McInnes I. B., Leung B., Wei X. Q., Gemmell C. C., Liew F. Y. Septic arthritis following Staphylococcus aureus infection in mice lacking inducible nitric oxide synthase. J Immunol. 1998 Jan 1;160(1):308–315. [PubMed] [Google Scholar]
  23. Novaro V., Rettori V., González E. T., Jawerbaum A., Faletti A., Canteros G., de Gimeno M. A. Interaction between uterine PGE and PGF2 alpha production and the nitridergic system during embryonic implantation in the rat. Prostaglandins. 1996 Jun;51(6):363–376. doi: 10.1016/0090-6980(96)00043-3. [DOI] [PubMed] [Google Scholar]
  24. Paul-Clark M., Del Soldato P., Fiorucci S., Flower R. J., Perretti M. 21-NO-prednisolone is a novel nitric oxide-releasing derivative of prednisolone with enhanced anti-inflammatory properties. Br J Pharmacol. 2000 Dec;131(7):1345–1354. doi: 10.1038/sj.bjp.0703704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Prete P. E., Gurakar-Osborne A. The contribution of synovial fluid lipoproteins to the chronic synovitis of rheumatoid arthritis. Prostaglandins. 1997 Oct;54(4):689–698. doi: 10.1016/s0090-6980(97)00147-0. [DOI] [PubMed] [Google Scholar]
  26. Sakurai H., Kohsaka H., Liu M. F., Higashiyama H., Hirata Y., Kanno K., Saito I., Miyasaka N. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest. 1995 Nov;96(5):2357–2363. doi: 10.1172/JCI118292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Salvemini D., Misko T. P., Masferrer J. L., Seibert K., Currie M. G., Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7240–7244. doi: 10.1073/pnas.90.15.7240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Salvemini D., Settle S. L., Masferrer J. L., Seibert K., Currie M. G., Needleman P. Regulation of prostaglandin production by nitric oxide; an in vivo analysis. Br J Pharmacol. 1995 Mar;114(6):1171–1178. doi: 10.1111/j.1476-5381.1995.tb13330.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Sano H., Hla T., Maier J. A., Crofford L. J., Case J. P., Maciag T., Wilder R. L. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest. 1992 Jan;89(1):97–108. doi: 10.1172/JCI115591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Stadler J., Harbrecht B. G., Di Silvio M., Curran R. D., Jordan M. L., Simmons R. L., Billiar T. R. Endogenous nitric oxide inhibits the synthesis of cyclooxygenase products and interleukin-6 by rat Kupffer cells. J Leukoc Biol. 1993 Feb;53(2):165–172. doi: 10.1002/jlb.53.2.165. [DOI] [PubMed] [Google Scholar]
  31. Stefanovic-Racic M., Meyers K., Meschter C., Coffey J. W., Hoffman R. A., Evans C. H. Comparison of the nitric oxide synthase inhibitors methylarginine and aminoguanidine as prophylactic and therapeutic agents in rat adjuvant arthritis. J Rheumatol. 1995 Oct;22(10):1922–1928. [PubMed] [Google Scholar]
  32. Stefanovic-Racic M., Meyers K., Meschter C., Coffey J. W., Hoffman R. A., Evans C. H. N-monomethyl arginine, an inhibitor of nitric oxide synthase, suppresses the development of adjuvant arthritis in rats. Arthritis Rheum. 1994 Jul;37(7):1062–1069. doi: 10.1002/art.1780370712. [DOI] [PubMed] [Google Scholar]
  33. Stefanovic-Racic M., Morales T. I., Taskiran D., McIntyre L. A., Evans C. H. The role of nitric oxide in proteoglycan turnover by bovine articular cartilage organ cultures. J Immunol. 1996 Feb 1;156(3):1213–1220. [PubMed] [Google Scholar]
  34. Stefanovic-Racic M., Möllers M. O., Miller L. A., Evans C. H. Nitric oxide and proteoglycan turnover in rabbit articular cartilage. J Orthop Res. 1997 May;15(3):442–449. doi: 10.1002/jor.1100150318. [DOI] [PubMed] [Google Scholar]
  35. Stoclet J. C., Muller B., Andriantsitohaina R., Kleschyov A. Overproduction of nitric oxide in pathophysiology of blood vessels. Biochemistry (Mosc) 1998 Jul;63(7):826–832. [PubMed] [Google Scholar]
  36. Swierkosz T. A., Mitchell J. A., Warner T. D., Botting R. M., Vane J. R. Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol. 1995 Apr;114(7):1335–1342. doi: 10.1111/j.1476-5381.1995.tb13353.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Tetsuka T., Daphna-Iken D., Srivastava S. K., Baier L. D., DuMaine J., Morrison A. R. Cross-talk between cyclooxygenase and nitric oxide pathways: prostaglandin E2 negatively modulates induction of nitric oxide synthase by interleukin 1. Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12168–12172. doi: 10.1073/pnas.91.25.12168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Ueki Y., Miyake S., Tominaga Y., Eguchi K. Increased nitric oxide levels in patients with rheumatoid arthritis. J Rheumatol. 1996 Feb;23(2):230–236. [PubMed] [Google Scholar]
  39. Van Eden Willem, Waksman Byron H. Immune regulation in adjuvant-induced arthritis: possible implications for innovative therapeutic strategies in arthritis. Arthritis Rheum. 2003 Jul;48(7):1788–1796. doi: 10.1002/art.11077. [DOI] [PubMed] [Google Scholar]
  40. Veihelmann A., Hofbauer A., Krombach F., Dorger M., Maier M., Refior H-J, Messmer K. Differential function of nitric oxide in murine antigen-induced arthritis. Rheumatology (Oxford) 2002 May;41(5):509–517. doi: 10.1093/rheumatology/41.5.509. [DOI] [PubMed] [Google Scholar]
  41. Veihelmann A., Landes J., Hofbauer A., Dorger M., Refior H. J., Messmer K., Krombach F. Exacerbation of antigen-induced arthritis in inducible nitric oxide synthase-deficient mice. Arthritis Rheum. 2001 Jun;44(6):1420–1427. doi: 10.1002/1529-0131(200106)44:6<1420::AID-ART237>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  42. al-Swayeh O. A., Clifford R. H., del Soldato P., Moore P. K. A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin. Br J Pharmacol. 2000 Jan;129(2):343–350. doi: 10.1038/sj.bjp.0703064. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES